| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7c006aabc2ad53119a94de8c17bda30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1db1284daa736f6ec6a137199496bba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_776a845c4ce3fc6cc0dd5fa4bb6d6b70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68bb5887c4ed27e4895530e422b303a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b27be245a13bfe83afab35759385f92 |
| publicationDate |
2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017035480-A1 |
| titleOfInvention |
Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist |
| abstract |
Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9957576-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11760810-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11591390-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10995152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11078272-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11608377-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11702474-B2 |
| priorityDate |
2015-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |